Phase II Trial of Bevacizumab in Combination With Pemetrexed as 2nd Line Therapy in Patients With Stable Brain Metastases From Non-small Cell Lung Cancer

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Eli Lilly and Company
Genentech
Information provided by (Responsible Party):
Heather Wakelee, Stanford University
ClinicalTrials.gov Identifier:
NCT00227019
First received: September 8, 2005
Last updated: August 6, 2013
Last verified: August 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: December 2015
  Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)